201 Brookline Avenue, Suite 901, Boston, Massachusetts 02215
Tango Therapeutics is incorporated in Delaware.
Tango Therapeutics was founded in 2017.
Tango Therapeutics’ shares are traded on the Nasdaq Capital Market under the symbol “TNGX”.
Tango went public via merger with BCTG Acquisition Corp. (BCTG), a special purpose acquisition company (SPAC), on August 11, 2021.
Tango Therapeutics’ fiscal year ends on December 31.
PricewaterhouseCoopers, LLP
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
87583X109
Shares of Tango Therapeutics’ stock can be purchased by contacting a securities broker of your choice.
No. Tango does not have a direct stock purchase plan. You may purchase shares of Tango through a broker of your choice.
Computershare Trust Company, N.A
For questions about your stock please contact our transfer agent, Computershare Trust Company, N.A., P.O. Box 43006, Providence, RI 02940-3006.
Quarterly & Annual reports and other investor materials are available in the “Investors” section of Tango Therapeutics’ corporate website. Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.
Please click here to be directed to the email alerts page.
For media and investor inquiries, please send an email to tango@argotpartners.com